RNF43-721

targets RNF43

Developed for: colorectal cancer
Investigated by: Human Genome Center, Institute of Medical Science, University of Tokyo · Kazuhiko Yoshimatsu

today NCT00641615 · Ph 1

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT00641615	May 2007 → Jul 2011	colorectal cancer	Kazuhiko Yoshimatsu	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	RNF43-721	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00641615 ↗
Target	RNF43	“RNF43-721 induces HLA A24 restricted specific cytotoxic T lymphocytes (CTL) against RNF43 expressed target.” NCT00641615 ↗